-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on Heron Therapeutics, Lowers Price Target to $2

Benzinga·06/03/2026 11:26:59
Listen to the news
HC Wainwright & Co. analyst Brandon Folkes maintains Heron Therapeutics (NASDAQ:HRTX) with a Buy and lowers the price target from $4 to $2.